SOP for UK CTA/Notifications via National Systems (Post-Brexit)
The purpose of this SOP is to define the process for submitting Clinical Trial Authorisations (CTAs) and related notifications to the Medicines and Healthcare products Regulatory Agency (MHRA) via UK national systems, in accordance with post-Brexit regulatory requirements. This ensures that trials conducted in the UK comply with local legislation, independent of EU systems.
Click to read the full article.
